10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

NAT2 Antibody (C-term) Blocking Peptide

Synthetic peptide
Catalog # BP6993b

Specification

NAT2 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession P11245

NAT2 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 10

Other Names
Arylamine N-acetyltransferase 2, Arylamide acetylase 2, N-acetyltransferase type 2, NAT-2, Polymorphic arylamine N-acetyltransferase, PNAT, NAT2, AAC2

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP6993b was selected from the C-term region of human NAT2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

NAT2 Antibody (C-term) Blocking Peptide - Protein Information

Name NAT2

Synonyms AAC2

Function
Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates (PubMed:12222688, PubMed:7915226). Participates in the detoxification of a plethora of hydrazine and arylamine drugs, and is able to bioactivate several known carcinogens.

Cellular Location
Cytoplasm.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

NAT2 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

NAT2 Antibody (C-term) Blocking Peptide - Images

NAT2 Antibody (C-term) Blocking Peptide - Background

NAT2 is an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens.

NAT2 Antibody (C-term) Blocking Peptide - References

Kim,S.H., et.al., Pharmacogenomics 10 (11), 1767-1779 (2009)